
Learn the Femoral endoprosthesis: MUTARS intercalary EPR (Implantcast) for pathological fracture of spindle cell sarcoma of bone surgical technique with step by step instructions on OrthOracle. Our e-learning platform contains high resolution images and a certified CME of the Femoral endoprosthesis: MUTARS intercalary EPR (Implantcast) for pathological fracture of spindle cell sarcoma of bone surgical procedure.
Osteosarcoma, Ewing’s sarcoma and chondrosarcoma are the three most common primary malignant sarcomas of bone. There are a number of other primary malignant bone sarcomas which do not fit neatly into one of the above three types, and these are generally known as ‘spindle cell sarcomas of bone’. They are rare and include such entities as fibrosarcoma, malignant fibrous histiocytoma and leiomyosarcoma
The most commonly effected anatomical sites are the femur followed by the tibia, pelvis and humerus. The typical age for a spindle cell sarcoma of bone is 45 years and 25% of patients present with a pathological fracture.
Endoprosthetic reconstruction of the femoral diaphysis, although scarcely reported in the literature, generally results in a reasonable functional outcome, allowing patients to bear weight and resume near normal function swiftly.
I use the Implantcast MUTARS diaphyseal endoprosthesis because (to my knowledge) it is the only silver coated, modular intercalary endoprosthesis on the market which also offers short and long reconstruction lengths (100 to 320mm), cemented or cement-less stems and if one of the implant stems loosens or fractures it can be converted to a proximal, or distal femoral endoprosthesis without explanting the other fixed stem.

INDICATIONS
The indications for intercalary femoral endoprosthetic replacement are to reconstruct massive bone defects following malignancy and rarely following infection and trauma. In oncology, tumours may either be primary or metastatic (secondary) bone tumours, or soft tissue sarcomas which have invaded the bone. Within this group pathological fractures may develop, where by the bone is weakened to the point of failure by the presence of the tumour.
SYMPTOMS & EXAMINATION
The symptoms of bone tumours are classically pain (which may initially be intermittent) and swelling, but patients may present with pathological fractures, as in this case. A history of preceding pain (particularly night pain with insidious onset) in the absence of an injury mechanism that would typically be consistent with a fracture at that anatomical location and age of the patient, should be considered suspicious for underlying malignancy or infection. On examination, patients are checked for distal neurovascular status, previous scars and surgeries, proximal lymphadenopathy and deformity in all planes.
IMAGING
The required imaging includes plain radiographs of the whole femur, MRI of the whole femur, CT of the chest and whole body bone scan. The patient will also have an image guided biopsy via a direct lateral approach using either CT or Fluoroscopy to obtain a tissue sample for immunohistochemical analysis to achieve a diagnosis. The biopsy is performed as soon as possible after imaging by the surgical team undertaking the eventual resection so that the biopsy tract is placed in the optimal position for en-bloc excision with the tumour.
The timing of imaging however is open to debate, in particular in the context of an acute fracture of a long-bone where early mobilisation is important. If comprehensive imaging is not going to alter management then aspects of it such as bone scans may be legitimately postponed in certain cases until after surgery.
ALTERNATIVE OPERATIVE TREATMENT
There are no endoprosthetic alternatives when contemplating a curative resection of pathological femoral fracture resection other than a total femoral endoprosthetic replacement.
In a more elective setting, biological reconstruction with allograft with or without vascularised fibula autograft, irradiated autograft and bone transport are alternatives, but obtaining allografts swiftly can be challenging in the UK, thus endoprosthetic reconstruction was favoured in this urgent fractured case.
NON-OPERATIVE MANAGEMENT
Radiotherapy or systemic chemotherapy are neo-adjuvant options for spindle cell sarcomas of bone, but in the presence of a fracture, surgical management was a priority.
CONTRAINDICATIONS
Active osteomyelitis.
Poor soft tissue coverage (if plastics surgical flap not available).
Insufficient proximal/distal bone stock to accept medullary stem necessitating total femoral endoprosthesis.

Right lateral position with routine hip props
Double alcoholic chlorhexidine skin preparation and Ioban incisional drapes
Monopolar diathermy and suction
Patient warming and invasive monitoring
Intravenous antibiotics thirty minutes prior to skin incision (flucloxacillin and gentamicin)

24 hours of intravenous antibiotic prophylaxis
Four weeks of low molecular weight heparin prophylaxis plus foot pumps until mobile and six weeks of thromboembolic stockings
Protected weight bearing for eight weeks and then graduate to full weight bearing by three months
Wound check 14 days
Routine X-rays post-operatively
Long-term, activities of daily living should be achieved but activities which promote failure such as skiing, horse riding, running are avoided although locomotion cycling is promoted.

Intercalary endoprostheses are associated with a high risk of aseptic loosening and implant fracture, due to the torsional forces at two bone-cement-implant interfaces. One recent paper reported that 36% of femoral intercalary EPRs had failed within five years (Failure rates and functional results for intercalary femur reconstructions after tumour resection, Albergo et al. Musculoskeletal Surg 2019).
Other options for the reconstruction of segmental diaphyseal femoral defects following oncological resection include autogenous vascularised fibular grafts, extracorporeal irradiation and reimplantation, combined allograft and fibular autografts (vascularised and non-vascularised) or segmental bone transport.
The five-and ten-year survival rates for primary spindle cell sarcomas of bone that had not metastasised at the time of diagnosis were 67% and 60%, respectively. The prognostic factors associated with decreased survival were similar to those those of patients with an osteosarcoma: large tumour size, older age, pathological fracture, need for amputation and poor response to pre-operative chemotherapy. Risk factors for local recurrence are also similar to those in patients with an osteosarcoma: close surgical margins and poor response to pre-operative chemotherapy (Prognostic factors and outcomes of spindle cell sarcomas of bone, Pakos et al. JBJS Br 2011).
Reference
- orthoracle.com





























































